Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Alipidem, Cerolip, Cetaxin, Cibrato, Cipide, Fixeril
Synonyms :
ciprofibrate, Ciprofibrato
Class :
Fibrates, Dyslipidaemic Agents, Lipid Modifying agents, Fibrate Antilipidemic Agent, Fibric Acid
Brand Name :
Alipidem, Cerolip, Cetaxin, Cibrato, Cipide, Fixeril
Synonyms :
ciprofibrate, Ciprofibrato
Class :
Fibrates, Dyslipidaemic Agents, Lipid Modifying agents, Fibrate Antilipidemic Agent, Fibric Acid
Dosage Forms & StrengthsÂ
TabletÂ
100 mgÂ
It is used in the therapy for Hyperlipidaemia with a recommended dose of 100 mg via oral administration taken per day
Dose Adjustments
Renal dose adjustment
In case of renal impairment, dose of ciprofibrate depends on CrCl. When CrCl falls between 30 and 80 ml/min dose of ciprofibrate reduced to 100 mg every alternate day. If CrCl is less than 30 ml/min, ciprofibrate is contraindicated
It is used in the therapy for Hyperlipidaemia with a recommended dose of 100 mg via oral administration taken per day
Dose Adjustments
Renal dose adjustment
In case of renal impairment, dose of ciprofibrate depends on CrCl. When CrCl falls between 30 and 80 ml/min dose of ciprofibrate reduced to 100 mg every alternate day. If CrCl is less than 30 ml/min, ciprofibrate is contraindicated
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
may diminish the absorption when combined with fibric acid derivatives
may increase the adverse effect of HMG-CoA Reductase Inhibitors
may increase the nephrotoxic effect of cyclosporine
may diminish the absorption when combined with fibric acid derivatives
it increases the toxicity of fibric derivatives
it increases the toxicity of fibric derivatives
it increases the toxicity of fibric derivatives
it increases the toxicity of fibric derivatives
it increases the toxicity of fibric derivatives
may intensify the potentially negative effects of HMG-CoA Reductase Inhibitors
fibric acid derivatives increase the toxicity of ezetimibe
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
ciprofibrate: it may enhance the serum concentration of HMG-CoA Reductase Inhibitors
ciprofibrate: it may enhance the serum concentration of HMG-CoA Reductase Inhibitors
ciprofibrate: it may enhance the serum concentration of HMG-CoA Reductase Inhibitors
ciprofibrate: it may enhance the serum concentration of HMG-CoA Reductase Inhibitors
ciprofibrate: it may enhance the serum concentration of HMG-CoA Reductase Inhibitors
may enhance the myopathic effect of colchicine
may increase the myopathic effect of Fibric Acid Derivatives
it increases the effect of myopathy on fibric acid derivatives
It may enhance the risk of adverse effects when combined with Atypical Antidepressants
It may enhance the risk of adverse effects when combined with Atypical Antidepressants
It may enhance the risk of adverse effects when combined with Atypical Antidepressants
when ciprofibrate is given along with acenocoumarol, there is an increased risk of bleeding
when ciprofibrate is given along with acenocoumarol, there is an increased risk of bleeding
when ciprofibrate is given along with warfarin, there is an increased risk of bleeding
there is an increased risk of myopathy, myoglobinuria, and rhabdomyolysis when vincristine is combined with ciprofibrate
Actions and Spectrum:Â
Actions:Â
Fibric acid derivative, ciprofibrate, has hypolipidemic action that is marked, which is shown by increasing HDL cholesterol levels and by reducing LDL and VLDL cholesterol levels, which further leads to reduced triglyceride levels.Â
Spectrum:Â
The hyperlipidemic action of ciprofibrate shows its spectrum of activity in the treatment of hyperlipidemia (severe or mixed) and hypertriglyceridemia.Â
Frequency not defined Â
alopeciaÂ
anorexiaÂ
diarrhoeaÂ
urticariaÂ
eczemaÂ
myalgiaÂ
peripheral neuropathyÂ
pulmonary fibrosisÂ
pancreatitisÂ
leukocytopeniaÂ
impotenceÂ
cytolysisÂ
rashesÂ
myositisÂ
headacheÂ
elevated CPK levelsÂ
headacheÂ
photosensitivityÂ
dyspepsiaÂ
vomitingÂ
nauseaÂ
abdominal painÂ
dizzinessÂ
rhabdomyolysisÂ
thrombocytopeniaÂ
fatigueÂ
pneumonitisÂ
somnolenceÂ
Black Box Warning:Â
Driving or operating machinery should be avoided while on ciprofibrate as it may cause dizziness. Smoking and alcohol should be stopped while taking this medication.Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
ciprofibrate is contraindicated in first trimester of pregnancy and should be avoided.Â
Breastfeeding warnings:Â Â
No published data is available.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
The hyperlipidemic action of ciprofibrate shows its spectrum of activity in the treatment of hyperlipidemia (severe or mixed) and hypertriglyceridemia. When cholesterol and triglyceride levels are high, ciprofibrate is used to reduce those levels by speeding or increasing the rate of metabolism of fats. Â
Pharmacodynamics:Â
When cholesterol and triglyceride levels are high, ciprofibrate is used to reduce those levels by speeding or increasing the rate of metabolism of fats. Fibric acid derivative, ciprofibrate, has hypolipidemic action that is marked, which is shown by increasing HDL cholesterol levels and by reducing LDL and VLDL cholesterol levels, which further leads to reduced triglyceride levels. Â
Pharmacokinetics:Â
AbsorptionÂ
ciprofibrate is readily absorbed from the GIT.Â
The time to achieve peak effect is 1-4 hoursÂ
DistributionÂ
Protein-bound is 98%Â
MetabolismÂ
Limited data available.Â
Elimination and ExcretionÂ
The half-life is 38-86 hours.Â
The drug is excreted via urine as glucuronide conjugates and as unchanged drug.Â
Administration:Â
Oral Administration of ciprofibrate can be taken with or without food. Some people will swallow the tablet while drinking water. The usual dose recommended is 100 mg per day.Â
Patient information leafletÂ
Generic Name: ciprofibrateÂ
Pronounced: SIGH-proh-fye-braytÂ
Why do we use ciprofibrate?Â
When cholesterol and triglyceride levels are high, ciprofibrate is used to reduce those levels by speeding or increasing the rate of metabolism of fats.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
